New FDA-Cleared Blood Pressure Monitor from Tenovi Supports Maternal Care and Stroke Prevention
As part of its commitment to preventive, accessible healthcare, Tenovi is launching the new Tenovi cellular-connected blood pressure monitor with irregular heartbeat detection, for use with Tenovi's large-size cuff. It is FDA-cleared for use in maternity care and for adults with diabetes, pregnancy, or preeclampsia.
Stroke is often linked to unmanaged chronic conditions such as hypertension. With 129 million Americans living with chronic illnesses, Tenovi is committed to closing care gaps and making preventive, proactive healthcare the norm.²
Tenovi recently advanced that mission by completing the AgeTech Collaborative™ from AARP Accelerator Program, an 8-week program designed to elevate promising early-stage AgeTech startups.
'Tenovi fully supports the mission of the AgeTech Collaborative™ from AARP to improve lives as people age,' said Nizan Friedman, Ph.D., CEO and co-founder of Tenovi. 'Our platform offers a seamless pathway for companies focused on better health outcomes to scale quickly through our network of over 180 remote patient monitoring partners. This collaboration expands access to innovative point solutions for seniors and reinforces our commitment to delivering comprehensive remote care across all disease states.'
Tenovi's remote monitoring platform enables clinicians to act early when warning signs, such as rising blood pressure may surface. Tenovi's proprietary Cellular Gateway connects over 40 FDA-cleared Bluetooth remote monitoring devices for vital signs, medication adherence, and activity tracking. The plug-and-play platform requires no apps, Wi-Fi, or syncing, and uses a simple red and green LED display system for added measurement adherence. The red light signals it's time for a patient to take a measurement. The green light confirms it was transmitted to their care team.
As Stroke Awareness Month continues, Tenovi remains focused on delivering real-time remote patient and therapeutic monitoring solutions that help prevent complications and improve outcomes for patients most at risk.
About Tenovi
Tenovi is a data aggregation and automation remote monitoring platform connecting medical device manufacturers with remote monitoring programs. It provides over 40 remote patient monitoring and remote therapeutic monitoring (RTM) device point solutions that integrate with its proprietary Cellular Gateway, automating the transfer of patient vitals. Tenovi's API-driven fulfillment and automation services enable seamless deployment of remote patient and therapeutic monitoring programs. To learn more, visit www.tenovi.com or follow on LinkedIn @tenovi, X @tenovihealth.
Sources
2 Hirsch, S. P., & Smith, L. M. (2024). Implementation of remote physiologic monitoring and remote therapeutic monitoring into a primary care practice to improve outcomes for patients with diabetes. Virginia, 2021–2023. Preventing Chronic Disease, 21, E20. Centers for Disease Control and Prevention. https://www.cdc.gov/pcd/issues/2024/23_0267.htm
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.
Hamilton Spectator
15 minutes ago
- Hamilton Spectator
US appeals court upholds West Virginia restriction on abortion pill sales
CHARLESTON, (AP) — A federal appeals court on Tuesday upheld a lower court's decision to restrict abortion pill sales in West Virginia. A three-judge panel of the 4th U.S. Circuit Court of Appeals in Richmond, Virginia, affirmed a ruling by a U.S. district judge in 2023 despite federal regulators' approval of the abortion pill as a safe and effective medication. Most Republican-controlled states have enacted or adopted abortion bans of some kind, including restricting abortion pills by default, since the U.S. Supreme Court in 2022 overturned Roe v. Wade , the 1973 ruling that provided nationwide access to abortion. All have been challenged in court. The Supreme Court ruled in the case of Dobbs v. Jackson Women's Health Organization. U.S. District Court Judge Robert C. Chambers had ruled that the near-total abortion ban signed by then-Republican Gov. Jim Justice in September 2022 took precedence over approvals from the U.S. Food and Drug Administration. 'For us to once again federalize the issue of abortion without a clear directive from Congress, right on the heels of Dobbs, would leave us one small step short of defiance,' 4th Circuit Judge J. Harvie Wilkinson III wrote for the court. 'One can of course agree or disagree with the Dobbs decision. But that is not the point,' Wilkinson said. 'At a time when the rule of law is under blunt assault, disregarding the Supreme Court is not an option.' West Virginia Gov. Patrick Morrisey, who took office in January, had defended challenges to the abortion law when he served as attorney general. 'Big win out of the 4th Circuit today,' Morrisey said in a statement. GenBioPro Inc., the country's only manufacturer of a generic version of the abortion pill mifepristone, had argued that the state cannot block access to a FDA-approved drug. Chambers had dismissed the majority of GenBioPro's challenges, finding there is 'no disputing that health, medicine, and medical licensure are traditional areas of state authority.' Appeals judge DeAndrea Gist Benjamin concurred and dissented in part Tuesday, calling it a 'troubling opinion.' 'Put plainly, this law erects barriers to life-saving healthcare for countless West Virginians in ways not envisioned by Congress,' Benjamin wrote. Not at issue in the appeal was a challenge by GenBioPro concerning a separate West Virginia law that stopped providers from prescribing mifepristone by telehealth. Chambers had allowed that challenge to proceed. The U.S. Supreme Court last year unanimously preserved access to mifepristone , which is used in nearly two-thirds of all abortions in the U.S. in 2023.
Yahoo
22 minutes ago
- Yahoo
What causes obesity? A major new study is upending common wisdom.
Obesity is uncommon among Hadza hunter-gatherers in Tanzania, Tsimane forager-farmers in Bolivia, Tuvan herder-farmers in Siberia, and other people in less-developed nations. But it's widespread among those of us in wealthy, highly industrialized nations. Why? A major study published this week in PNAS brings surprising clarity to that question. Using objective data about metabolic rates and energy expenditure among more than 4,000 men and women living in dozens of nations across a broad spectrum of socioeconomic conditions, the study quantified how many calories people from different cultures burn most days. Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. For decades, common wisdom and public health messaging have assumed that people in highly developed nations, like the United States, are relatively sedentary and burn far fewer daily calories than people in less-industrialized countries, greatly increasing the risk for obesity. But the new study says no. Instead, it finds that Americans, Europeans and people living in other developed nations expend about the same number of total calories most days as hunter-gatherers, herders, subsistence farmers, foragers and anyone else living in less-industrialized nations. That unexpected finding almost certainly means inactivity is not the main cause of obesity in the U.S. and elsewhere, said Herman Pontzer, a professor of evolutionary anthropology and global health at Duke University in North Carolina and a senior author of the new study. What is, then? The study offers provocative hints about the role of diet and some of the specific foods we eat, as well as about the limits of exercise, and the best ways, in the long run, to avoid and treat obesity. - - - Is diet or inactivity causing obesity? 'There's still a lively debate in public health about the role of diet and activity' in the development of obesity, Pontzer said, especially in wealthy nations. Some experts believe we're exercising too little, others that we're eating too much, and still more that the two contribute almost equally. Understanding the relative contributions of diet and physical activity is important, Pontzer noted, because we can't effectively help people with obesity unless we first tease out its origins. But few large-scale studies have carefully compared energy expenditure among populations prone to obesity against those more resistant to it, which would be a first step toward figuring out what drives weight gain. So, for the new study, Pontzer and his 80-plus co-authors gathered existing data from labs around the world that use doubly labeled water in metabolism studies. Doubly labeled water contains isotopes that, when excreted in urine or other fluids, allow researchers to precisely determine someone's energy expenditure, metabolic rates and body-fat percentage. It's the gold standard in this kind of research. They wound up with data for 4,213 men and women from 34 countries or cultural groups, running the socioeconomic gamut from tribes in Africa to executives in Norway. They calculated total daily energy expenditures for everyone, along with their basal energy expenditure, which is the number of calories our bodies burn during basic, biological operations, and physical activity energy expenditure, which is how many calories we use while moving around. - - - A new theory of how our metabolisms work After adjusting for body size (since people in wealthy nations tend to have larger bodies, and larger bodies burn more calories), they started comparing different groups. Anyone expecting a wide range of energy expenditures, with hunter-gatherers and farmer-herders at the high end and deskbound American office workers trailing well behind, would be wrong. Across the board, the total daily energy expenditures of the 4,213 people were quite similar, no matter where they lived or how they spent their lives. Although the hunter-gatherers and other similar groups moved around far more throughout the day than a typical American, their overall daily calorie burns were nearly the same. The findings, though counterintuitive, align with a new theory about our metabolisms, first proposed by Pontzer. Known as the constrained total energy expenditure model, it says that our brains and bodies closely monitor our total energy expenditure, keeping it within a narrow range. If we start consistently burning extra calories by, for instance, stalking prey on foot for days or training for a marathon, our brains slow down or shut off some tangential biological operations, often related to growth, and our overall daily calorie burn stays within a consistent band. - - - The role of ultra-processed foods The upshot is that 'there is no effect of economic development on size-adjusted physical activity expenditure,' Pontzer says. In which case, the fundamental problem isn't that we're moving too little, meaning more exercise is unlikely to reduce obesity much. What could, then? 'Our analyses suggest that increased energy intake has been roughly 10 times more important than declining total energy expenditure in driving the modern obesity crisis,' the study authors write. In other words, we're eating too much. We may also be eating the wrong kinds of foods, the study also suggests. In a sub-analysis of the diets of some of the groups from both highly and less-developed nations, the scientists found a strong correlation between the percentage of daily diets that consists of 'ultra-processed foods' - which the study's authors define as 'industrial formulations of five or more ingredients' - and higher body-fat percentages. We are, to be blunt, eating too much and probably eating too much of the wrong foods. 'This study confirms what I've been saying, which is that diet is the key culprit in our current [obesity] epidemic,' said Barry Popkin, a professor at the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill and an obesity expert. 'This is a well-done study,' he added. Other experts agree. 'It's clear from this important new research and other studies that changes to our food, not our activity, are the dominant drivers of obesity,' said Dariush Mozaffarian, director of the Food is Medicine Institute at Tufts University in Boston. The findings don't mean, though, that exercise is unimportant, Pontzer emphasized. 'We know that exercise is essential for health. This study doesn't change that,' he said. But the study does suggest that 'to address obesity, public health efforts need to focus on diet,' he said, especially on ultra-processed foods, 'that seem to be really potent causes of obesity.' Related Content He may have stopped Trump's would-be assassin. Now he's telling his story. He seeded clouds over Texas. Then came the conspiracy theories. How conservatives beat back a Republican sell-off of public lands
